Loading…

PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia

Aims The B7 family check‐point molecules are potential therapeutic targets in cancer immunotherapy. However, their expression status in human gestational trophoblastic neoplasia (GTN) remains unknown. We investigated the expression profiles of the B7 family check‐point proteins PD‐L1, PD‐L2, B7‐H3,...

Full description

Saved in:
Bibliographic Details
Published in:Histopathology 2019-09, Vol.75 (3), p.421-430
Main Authors: Zong, Liju, Zhang, Ming, Wang, Wenze, Wan, Xirun, Yang, Junjun, Xiang, Yang
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713
cites cdi_FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713
container_end_page 430
container_issue 3
container_start_page 421
container_title Histopathology
container_volume 75
creator Zong, Liju
Zhang, Ming
Wang, Wenze
Wan, Xirun
Yang, Junjun
Xiang, Yang
description Aims The B7 family check‐point molecules are potential therapeutic targets in cancer immunotherapy. However, their expression status in human gestational trophoblastic neoplasia (GTN) remains unknown. We investigated the expression profiles of the B7 family check‐point proteins PD‐L1, PD‐L2, B7‐H3, B7‐H4, VISTA and B7‐H6 in GTN and their clinical significance. Methods and results We identified 112 patients with GTN, including 68 with choriocarcinoma, 33 with placental‐site trophoblastic tumour (PSTT) and 11 with epithelioid trophoblastic tumour (ETT). Immunohistochemical staining was performed on whole‐tissue GTN sections using anti‐B7 family antibodies. VISTA expression was immunohistochemically analysed using microarrays of normal human tissues and of 20 common cancers. PD‐L1 and B7‐H3 were highly expressed in all GTN tumours, while PD‐L2 was expressed in 87.5% of the samples. B7‐H4 and B7‐H6 were negative in 100% and 98.2% of the samples, respectively. PD‐L1, B7‐H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs. There was no association between B7 family check‐point expression in tumour cells and disease stage, prognostic score or patient outcomes (complete remission versus death). VISTA protein was widely overexpressed in 98.2% of all the GTN, but its expression varied in other cancer types and was negative in normal adult and fetal tissues except placental trophoblasts and splenic lymphocytes. Conclusions The GTN trophoblast cells show high expression of PD‐L1, B7‐H3 and VISTA in a manner that is independent of clinical outcomes. These proteins may be potential immunotherapeutic targets when treating GTN.
doi_str_mv 10.1111/his.13882
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2213929114</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2272999678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713</originalsourceid><addsrcrecordid>eNp10EtOwzAQBmALgaAUFlwAWWIDEqEeO_FjybuVKoHEYxs5iUOM0ibYqaA7jsAZOQkuLSyQ8GZm8enX-EdoD8gJhDeorD8BJiVdQz1gPIlokqh11COMqIgAF1to2_tnQkAwSjfRFgMCjHHSQ4-3F5_vH2M4xmciLEOG9bTAj6O7-1OsncGVfarqOTZvrTPemwLbKX4yvtOdbaa6xp1r2qrJau07m-OpadqwWr2DNkpde7O7mn30cHV5fz6MxjfXo_PTcZTHoGhUas1FIstc5aYEypLSZNxkCVeESAlc0jjLiSIxo7ERNMlkzIyWgudKFYUA1keHy9zWNS-zcFc6sT43da3DKTOfUgpMUQUQB3rwhz43Mxf-sFCCKqW4kEEdLVXuGu-dKdPW2Yl28xRIuig7DWWn32UHu79KnGUTU_zKn3YDGCzBq63N_P-kdDi6W0Z-AQIIh6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2272999678</pqid></control><display><type>article</type><title>PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia</title><source>Wiley</source><creator>Zong, Liju ; Zhang, Ming ; Wang, Wenze ; Wan, Xirun ; Yang, Junjun ; Xiang, Yang</creator><creatorcontrib>Zong, Liju ; Zhang, Ming ; Wang, Wenze ; Wan, Xirun ; Yang, Junjun ; Xiang, Yang</creatorcontrib><description>Aims The B7 family check‐point molecules are potential therapeutic targets in cancer immunotherapy. However, their expression status in human gestational trophoblastic neoplasia (GTN) remains unknown. We investigated the expression profiles of the B7 family check‐point proteins PD‐L1, PD‐L2, B7‐H3, B7‐H4, VISTA and B7‐H6 in GTN and their clinical significance. Methods and results We identified 112 patients with GTN, including 68 with choriocarcinoma, 33 with placental‐site trophoblastic tumour (PSTT) and 11 with epithelioid trophoblastic tumour (ETT). Immunohistochemical staining was performed on whole‐tissue GTN sections using anti‐B7 family antibodies. VISTA expression was immunohistochemically analysed using microarrays of normal human tissues and of 20 common cancers. PD‐L1 and B7‐H3 were highly expressed in all GTN tumours, while PD‐L2 was expressed in 87.5% of the samples. B7‐H4 and B7‐H6 were negative in 100% and 98.2% of the samples, respectively. PD‐L1, B7‐H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs. There was no association between B7 family check‐point expression in tumour cells and disease stage, prognostic score or patient outcomes (complete remission versus death). VISTA protein was widely overexpressed in 98.2% of all the GTN, but its expression varied in other cancer types and was negative in normal adult and fetal tissues except placental trophoblasts and splenic lymphocytes. Conclusions The GTN trophoblast cells show high expression of PD‐L1, B7‐H3 and VISTA in a manner that is independent of clinical outcomes. These proteins may be potential immunotherapeutic targets when treating GTN.</description><identifier>ISSN: 0309-0167</identifier><identifier>EISSN: 1365-2559</identifier><identifier>DOI: 10.1111/his.13882</identifier><identifier>PMID: 31013360</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; B7 antigen ; B7 Antigens - biosynthesis ; B7 family checkpoints ; B7-H1 Antigen - biosynthesis ; B7‐H3 ; Biomarkers, Tumor - analysis ; Cancer immunotherapy ; Female ; Fetuses ; Gestational Trophoblastic Disease - metabolism ; Gestational Trophoblastic Disease - pathology ; gestational trophoblastic neoplasia ; Humans ; Immunotherapy ; Lymphocytes ; Middle Aged ; Patients ; PD-L1 protein ; PD‐L1 ; Placenta ; Pregnancy ; Remission ; Spleen ; Therapeutic applications ; Trophoblasts ; Tumors ; VISTA ; Young Adult</subject><ispartof>Histopathology, 2019-09, Vol.75 (3), p.421-430</ispartof><rights>2019 John Wiley &amp; Sons Ltd</rights><rights>2019 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2019 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713</citedby><cites>FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713</cites><orcidid>0000-0002-5625-0119</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31013360$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zong, Liju</creatorcontrib><creatorcontrib>Zhang, Ming</creatorcontrib><creatorcontrib>Wang, Wenze</creatorcontrib><creatorcontrib>Wan, Xirun</creatorcontrib><creatorcontrib>Yang, Junjun</creatorcontrib><creatorcontrib>Xiang, Yang</creatorcontrib><title>PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia</title><title>Histopathology</title><addtitle>Histopathology</addtitle><description>Aims The B7 family check‐point molecules are potential therapeutic targets in cancer immunotherapy. However, their expression status in human gestational trophoblastic neoplasia (GTN) remains unknown. We investigated the expression profiles of the B7 family check‐point proteins PD‐L1, PD‐L2, B7‐H3, B7‐H4, VISTA and B7‐H6 in GTN and their clinical significance. Methods and results We identified 112 patients with GTN, including 68 with choriocarcinoma, 33 with placental‐site trophoblastic tumour (PSTT) and 11 with epithelioid trophoblastic tumour (ETT). Immunohistochemical staining was performed on whole‐tissue GTN sections using anti‐B7 family antibodies. VISTA expression was immunohistochemically analysed using microarrays of normal human tissues and of 20 common cancers. PD‐L1 and B7‐H3 were highly expressed in all GTN tumours, while PD‐L2 was expressed in 87.5% of the samples. B7‐H4 and B7‐H6 were negative in 100% and 98.2% of the samples, respectively. PD‐L1, B7‐H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs. There was no association between B7 family check‐point expression in tumour cells and disease stage, prognostic score or patient outcomes (complete remission versus death). VISTA protein was widely overexpressed in 98.2% of all the GTN, but its expression varied in other cancer types and was negative in normal adult and fetal tissues except placental trophoblasts and splenic lymphocytes. Conclusions The GTN trophoblast cells show high expression of PD‐L1, B7‐H3 and VISTA in a manner that is independent of clinical outcomes. These proteins may be potential immunotherapeutic targets when treating GTN.</description><subject>Adult</subject><subject>B7 antigen</subject><subject>B7 Antigens - biosynthesis</subject><subject>B7 family checkpoints</subject><subject>B7-H1 Antigen - biosynthesis</subject><subject>B7‐H3</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cancer immunotherapy</subject><subject>Female</subject><subject>Fetuses</subject><subject>Gestational Trophoblastic Disease - metabolism</subject><subject>Gestational Trophoblastic Disease - pathology</subject><subject>gestational trophoblastic neoplasia</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>PD-L1 protein</subject><subject>PD‐L1</subject><subject>Placenta</subject><subject>Pregnancy</subject><subject>Remission</subject><subject>Spleen</subject><subject>Therapeutic applications</subject><subject>Trophoblasts</subject><subject>Tumors</subject><subject>VISTA</subject><subject>Young Adult</subject><issn>0309-0167</issn><issn>1365-2559</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp10EtOwzAQBmALgaAUFlwAWWIDEqEeO_FjybuVKoHEYxs5iUOM0ibYqaA7jsAZOQkuLSyQ8GZm8enX-EdoD8gJhDeorD8BJiVdQz1gPIlokqh11COMqIgAF1to2_tnQkAwSjfRFgMCjHHSQ4-3F5_vH2M4xmciLEOG9bTAj6O7-1OsncGVfarqOTZvrTPemwLbKX4yvtOdbaa6xp1r2qrJau07m-OpadqwWr2DNkpde7O7mn30cHV5fz6MxjfXo_PTcZTHoGhUas1FIstc5aYEypLSZNxkCVeESAlc0jjLiSIxo7ERNMlkzIyWgudKFYUA1keHy9zWNS-zcFc6sT43da3DKTOfUgpMUQUQB3rwhz43Mxf-sFCCKqW4kEEdLVXuGu-dKdPW2Yl28xRIuig7DWWn32UHu79KnGUTU_zKn3YDGCzBq63N_P-kdDi6W0Z-AQIIh6Q</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Zong, Liju</creator><creator>Zhang, Ming</creator><creator>Wang, Wenze</creator><creator>Wan, Xirun</creator><creator>Yang, Junjun</creator><creator>Xiang, Yang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5625-0119</orcidid></search><sort><creationdate>201909</creationdate><title>PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia</title><author>Zong, Liju ; Zhang, Ming ; Wang, Wenze ; Wan, Xirun ; Yang, Junjun ; Xiang, Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>B7 antigen</topic><topic>B7 Antigens - biosynthesis</topic><topic>B7 family checkpoints</topic><topic>B7-H1 Antigen - biosynthesis</topic><topic>B7‐H3</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cancer immunotherapy</topic><topic>Female</topic><topic>Fetuses</topic><topic>Gestational Trophoblastic Disease - metabolism</topic><topic>Gestational Trophoblastic Disease - pathology</topic><topic>gestational trophoblastic neoplasia</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>PD-L1 protein</topic><topic>PD‐L1</topic><topic>Placenta</topic><topic>Pregnancy</topic><topic>Remission</topic><topic>Spleen</topic><topic>Therapeutic applications</topic><topic>Trophoblasts</topic><topic>Tumors</topic><topic>VISTA</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zong, Liju</creatorcontrib><creatorcontrib>Zhang, Ming</creatorcontrib><creatorcontrib>Wang, Wenze</creatorcontrib><creatorcontrib>Wan, Xirun</creatorcontrib><creatorcontrib>Yang, Junjun</creatorcontrib><creatorcontrib>Xiang, Yang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Histopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zong, Liju</au><au>Zhang, Ming</au><au>Wang, Wenze</au><au>Wan, Xirun</au><au>Yang, Junjun</au><au>Xiang, Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia</atitle><jtitle>Histopathology</jtitle><addtitle>Histopathology</addtitle><date>2019-09</date><risdate>2019</risdate><volume>75</volume><issue>3</issue><spage>421</spage><epage>430</epage><pages>421-430</pages><issn>0309-0167</issn><eissn>1365-2559</eissn><abstract>Aims The B7 family check‐point molecules are potential therapeutic targets in cancer immunotherapy. However, their expression status in human gestational trophoblastic neoplasia (GTN) remains unknown. We investigated the expression profiles of the B7 family check‐point proteins PD‐L1, PD‐L2, B7‐H3, B7‐H4, VISTA and B7‐H6 in GTN and their clinical significance. Methods and results We identified 112 patients with GTN, including 68 with choriocarcinoma, 33 with placental‐site trophoblastic tumour (PSTT) and 11 with epithelioid trophoblastic tumour (ETT). Immunohistochemical staining was performed on whole‐tissue GTN sections using anti‐B7 family antibodies. VISTA expression was immunohistochemically analysed using microarrays of normal human tissues and of 20 common cancers. PD‐L1 and B7‐H3 were highly expressed in all GTN tumours, while PD‐L2 was expressed in 87.5% of the samples. B7‐H4 and B7‐H6 were negative in 100% and 98.2% of the samples, respectively. PD‐L1, B7‐H3 and VISTA levels were significantly higher in choriocarcinomas and PSTTs than in ETTs. There was no association between B7 family check‐point expression in tumour cells and disease stage, prognostic score or patient outcomes (complete remission versus death). VISTA protein was widely overexpressed in 98.2% of all the GTN, but its expression varied in other cancer types and was negative in normal adult and fetal tissues except placental trophoblasts and splenic lymphocytes. Conclusions The GTN trophoblast cells show high expression of PD‐L1, B7‐H3 and VISTA in a manner that is independent of clinical outcomes. These proteins may be potential immunotherapeutic targets when treating GTN.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>31013360</pmid><doi>10.1111/his.13882</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-5625-0119</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0309-0167
ispartof Histopathology, 2019-09, Vol.75 (3), p.421-430
issn 0309-0167
1365-2559
language eng
recordid cdi_proquest_miscellaneous_2213929114
source Wiley
subjects Adult
B7 antigen
B7 Antigens - biosynthesis
B7 family checkpoints
B7-H1 Antigen - biosynthesis
B7‐H3
Biomarkers, Tumor - analysis
Cancer immunotherapy
Female
Fetuses
Gestational Trophoblastic Disease - metabolism
Gestational Trophoblastic Disease - pathology
gestational trophoblastic neoplasia
Humans
Immunotherapy
Lymphocytes
Middle Aged
Patients
PD-L1 protein
PD‐L1
Placenta
Pregnancy
Remission
Spleen
Therapeutic applications
Trophoblasts
Tumors
VISTA
Young Adult
title PD‐L1, B7‐H3 and VISTA are highly expressed in gestational trophoblastic neoplasia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A46%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PD%E2%80%90L1,%20B7%E2%80%90H3%20and%20VISTA%20are%20highly%20expressed%20in%20gestational%20trophoblastic%20neoplasia&rft.jtitle=Histopathology&rft.au=Zong,%20Liju&rft.date=2019-09&rft.volume=75&rft.issue=3&rft.spage=421&rft.epage=430&rft.pages=421-430&rft.issn=0309-0167&rft.eissn=1365-2559&rft_id=info:doi/10.1111/his.13882&rft_dat=%3Cproquest_cross%3E2272999678%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4192-faa6758fc9cef1235feb6eb569008816824bc0904324e725b843ea876c99dd713%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2272999678&rft_id=info:pmid/31013360&rfr_iscdi=true